Calidi Biotherapeutics, Inc. Overview
Pro stress-test →Calidi Biotherapeutics is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, using its proprietary RedTail platform featuring an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.
Strategic Profile
Pro stress-test →The company's lead candidate CLD-401 is a systemically delivered oncolytic virus designed to express IL-15 superagonist only in the tumor microenvironment and is currently in IND-enabling studies, with clinical entry expected following IND filing by end of 2026. The RedTail platform has been expanded with a new approach of in situ T-cell engagers.
Competitive Landscape
Pro stress-test →Calidi competes in the oncolytic virus and genetic medicine delivery space against established virotherapy platforms and cell therapy approaches. Direct competitors include other systemic virotherapy developers like Turnstone Biologics and Replimune, as well as broader immuno-oncology approaches from companies pursuing CAR-T and bispecific T-cell engagers (BiTEs) delivered through alternative modalities.
Industry Context
Calidi Biotherapeutics, Inc. operates in Oncolytic virus immunotherapy.
Key facts
Founded: Information not available in search results · Headquarters: San Diego, US · Employees: Not publicly disclosed · Revenue: $0 (pre-revenue) · Market cap: ~$26M (based on ~$0.17 stock price as of June 26, 2026)